ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,604,250 | -80.7% | 45,000 | -75.0% | 0.02% | -83.8% |
| Q2 2023 | $8,303,400 | +165.4% | 180,000 | +130.7% | 0.15% | +146.7% |
| Q1 2023 | $3,128,762 | +48.4% | 78,024 | +71.5% | 0.06% | +87.5% |
| Q4 2022 | $2,108,015 | -80.2% | 45,500 | -82.3% | 0.03% | -78.2% |
| Q3 2022 | $10,643,000 | -45.2% | 257,100 | -21.0% | 0.15% | -45.1% |
| Q2 2022 | $19,422,000 | +192.7% | 325,534 | +256.2% | 0.27% | +235.0% |
| Q1 2022 | $6,636,000 | -27.3% | 91,400 | +14.0% | 0.08% | -59.2% |
| Q1 2021 | $9,131,000 | +140.7% | 80,201 | +192.7% | 0.20% | +127.9% |
| Q4 2020 | $3,794,000 | -14.5% | 27,400 | -49.3% | 0.09% | -17.3% |
| Q3 2020 | $4,436,000 | -48.3% | 54,000 | -50.8% | 0.10% | -63.6% |
| Q2 2020 | $8,581,000 | +394.9% | 109,700 | +338.8% | 0.29% | +197.9% |
| Q1 2019 | $1,734,000 | – | 25,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |